HIGHLAND-EUROPE
Highland Europe today announces that it has closed its fifth fund, raising €1 billion to double down on its strategy of backing the Continent’s most outstanding founder-led teams in software and internet businesses. David Blyghton, who joined Highland Europe in 2014, is promoted to Partner, a clear indication of Highland Europe’s commitment to nurturing internal talent.
Highland Europe has raised a total of €2.75 billion and has invested in companies such as Adjust, AMCS, Camunda, ContentSquare, Descartes, Deepki, eGym, Featurespace, GetYourGuide, Huel, Jellysmack, Malwarebytes, MatchesFashion, Me+Em, Nexthink, Podimo, Spot, Supermetrics, WeTransfer, Wolt and Zwift.
Fergal Mullen, Partner, said: “We want to thank all of those European founders who chose to partner with us over the past ten years. It is their ambition, talent and drive that inspires us as we build category-defining businesses together. Current market conditions are not easy, but our founder-led companies continue to scale impressively and efficiently, with several world-leaders in the mix. We’re pleased that our investors share our conviction and thank them for their continued trust.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005315/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 00:00:00 CET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem samarbejde med VaporVM12.11.2025 23:54:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for digital transformation og cybersikkerhed med tilføjelsen af samarbejdspartneren VaporVM, der er et cloud-native teknologifirma med hovedsæde i Dubai. VaporVM, der blev grundlagt i 2017, hjælper globale virksomheder med at navigere i digital transformation gennem integrerede cloud-tjenester, DevOps, cybersikkerhed, datavidenskab og modernisering af applikationer. Med fokus på skalerbarhed og hurtigere lanceringer arbejder firmaet med Fortune 500-virksomheder og udnytter deres ekspertise og automatisering til at effektivisere it-drift og fremskynde digitale resultater. "Hos VaporVM brænder vi for at hjælpe virksomheder med ikke bare at tage nye teknologier til sig, men også at gentænke, hvad der kan lade sig gøre, når de bruges til at skabe reel forandring," siger Aqeel Asim, der er CEO og grundlægger af VaporVM. "Samarbejdet med Andersen Consulting giver os mulighed for at løfte vores mission til et globalt niveau – så vi kan bringe
Valorem Reply recognized as Winner of 2025 Microsoft Inclusion Changemaker Partner of the Year12.11.2025 21:30:00 CET | Press release
Valorem Reply, the Reply Group company specializing in Microsoft technologies and AI-driven, cloud-native solutions, announced today it has won the 2025 Microsoft Inclusion Changemaker Partner of the Year Award. The company was honored among a global field of top Microsoft partners for demonstrating excellence in innovation and implementation of customer solutions based on Microsoft technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112917859/en/ The Inclusion Changemaker Partner of the Year Award celebrates partners that lead with inclusive design, accessibility, and innovation to help customers and communities achieve more. “We’re proud of Valorem Reply for earning this recognition,” said Filippo Rizzante, CTO at Reply. “Their work exemplifies our shared commitment to inclusion and to using technology as a catalyst for opportunity and meaningful change. This award reflects the dedication and creativity of the Va
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom